RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic <i>EGFR</i>-mutated NSCLC.

ABSTRACT:

Aim

The global phase III RELAY trial demonstrated the efficacy of ramucirumab (RAM) plus erlotinib (ERL) in patients with untreated metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). We present safety and efficacy profiles of RAM+ERL in Japanese elderly (aged ≥ 75 years) patients in RELAY.

Methods

Patients were randomized (1:1) to RAM (10 mg/kg) or placebo (PL) intravenously every 2 weeks plus 150 mg/day ERL orally. Primary endpoint was progression-free survival (reported elsewhere). This report describes response rates, study drug exposure, dose adjustments, safety, and post-study treatment discontinuation therapies in Japanese elderly patients (RAM+ERL, n = 12; PL+ERL, n = 17).

Results

Overall response rate was simi

SUBMITTER: Nishino K 

PROVIDER: S-EPMC12520095 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature